This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Close Message for pharmaceutical industry jobs
Media Contacts is dedicated to putting job seekers looking for pharmaceutical industry jobs in touch with recruiters and employers.
Browse Jobs Search Jobs
France (103)
Germany (89)
Belgium (59)
Italy (48)
Australia (19)
Spain (13)
Hungary (8)
Denmark (7)
Austria (6)
Singapore (2)
Canada (1)
Iran (1)
Turkey (1)

To receive a FREE weekly email alert of all the latest pharmaceutical industry jobs added to our database enter your email address below.

Submit | Tell me more...

Sister sites:
Our sister site Our sister site
Partner sites:

At Burntsky Limited we work with a number of third parties in order to maximise the reach of the jobs posted with us including but not limited to:

JooblePartner Jooble
UK Jobs
Science Jobs

Industry News
01 October 2020 13:01Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
FREMONT, Calif., Oct. 1, 2020 /PRNewswire/ -- Boehringer Ingelheim today announced that Lars Dreesmann, PhD, has been named President of the company's US biopharmaceutical development and manufacturing business, Boehringer Ingelheim Fremont, Inc.,

01 October 2020 13:00Debiopharm lance TrilynX - un essai clinique de phase III destiné à obtenir l'enregistrement du xevinapant pour le traitement du cancer de la tête et du cou
TrilynX est une étude de phase III randomisée et contrôlée en double aveugle chez des patients à haut risque atteints d'un carcinome épidermoïde de la tête et du cou localement avancé (LA-SCCHN). Les patients reçoivent le xevinapant (Debio 1143) o

01 October 2020 13:00Debiopharm Launches TrilynX - a Large-scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer
First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCH

01 October 2020 13:00CRB design-build with Grand River Aseptic Manufacturing picked to manufacture COVID-19 solution
KANSAS CITY, Mo., Oct. 1, 2020 /PRNewswire/ -- CRB, a market-leading provider of integrated project delivery solutions for vaccine and critical therapy manufacturers, recently completed the design and construction of a large-scale facility for Gra

01 October 2020 13:00CNS Pharmaceuticals Achieves Critical Manufacturing Milestone
HOUSTON, Oct. 1, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central ner

01 October 2020 13:00HealthLynked Corp. Partners with Commonwealth Primary Care Accountable Care Organization (ACO)
NAPLES, Fla., Oct. 1, 2020 /PRNewswire/ -- HealthLynked Corp. (OTCQB: HLYK), a global healthcare network focused on care management of its members and healthcare technologies connecting doctors, patients and medical data, today announced its collab

01 October 2020 12:00BC Platforms Announces Colorado Center for Personalized Medicine Joins Global Data Partner Network to advance Personalized Healthcare Research
ZURICH and BOSTON, Oct. 1, 2020 /PRNewswire/ -- BC Platforms, a global leader in clinical and genomic data management, analytics and access, today announced that it has formed a new data partnership with the Colorado Center for Personalized Medicin

01 October 2020 12:00CiVi Biopharma Resumes AURORA Phase 3 Clinical Trial of CIVI030 to Treat Systemic Sclerosis
CHEVY CHASE, Md., Oct. 1, 2020 /PRNewswire/ -- CiVi Biopharma, Inc., ("CiVi" or "the Company"), a privately held company focused on creating novel therapies against diseases where the unmet medical need exists, today announces that the Company, th

01 October 2020 11:45Glucose Health, Inc. 3Rd Quarter 2020 Preliminary Results Indicate 80% Revenue Increase
BENTONVILLE, Ark., Oct. 1, 2020 /PRNewswire/ -- Glucose Health, Inc. (OTC: GLUC) today advised that preliminary sales figures indicate an 80% revenue increase for the 3rd quarter ending September 30, 2020, vs the prior quarterly period, ending Sept

01 October 2020 11:00Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration a

01 October 2020 09:00The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020
STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the last visit of the 200th patient has taken place in Part A of the pivotal NeflgArd Phase 3 study The NefIgArd trial is studying the eff

01 October 2020 08:46Dutch Vico Therapeutics strengthens leadership team with the appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent Director
- Dr. Sandbrink, M.D., Ph.D. is a highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Topas, Bayer and Schering.  - Dr. Hinsby, Ph.D. is a seasoned life science entrepr

01 October 2020 08:05Enesi Pharma's ImplaVax® Solid-Dose and Needle-Free Vaccination Platform Wins Best New Vaccine Technology/Platform Award at the World Vaccine Congress
OXFORD, England, Oct. 1, 2020 /PRNewswire/ -- Enesi Pharma ("Enesi"), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technolog

01 October 2020 07:43IRLAB's mesdopetam IND accepted by the US FDA
STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the U.S. Food and Drug Administration (FDA) has accepted IRLAB's investigational new drug application (IND) for the drug candidate mesdopetam (IRL790). T

01 October 2020 07:15Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
STOCKHOLM, Oct. 1, 2020 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. Melflufen (INN melphalan flufenamide), is cu

01 October 2020 06:55Photocure launches European Hexvix operations
OSLO, Norway, Oct. 1, 2020 /PRNewswire/ -- Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition

30 September 2020 22:43Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the phase 2 COMPARE study comparing the efficacy of

30 September 2020 21:53DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference
CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. WeiQi Lin, Executive Vice President of R&D will be pa

30 September 2020 21:05Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
CARLSBAD, Calif., Sept. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ION373 for th

30 September 2020 21:05Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
RED BANK, N.J., Sept. 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the submission of the clinical module of the Company's
News last updated 01/10/2020 13:07:40
line graphic

Compatible with:

JobMate   Broadbean   Idibu

Site optimised for Internet Explorer 8+ / Firefox 3+
View a complete Jobs Listing

Credit cards image